NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
28 trialsNCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT05220722 2025-10-23
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
Phase 1/2 Terminated
NCT06848556 2025-02-27
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT05497453 2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2 Terminated
NCT02314052 2024-07-11
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Novo Nordisk A/S
Phase 1/2 Terminated
NCT03422679 2024-01-16
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Phase 1/2 Terminated
NCT03867370 2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Terminated
NCT03945799 2022-08-31
A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
Zhejiang University
Phase 1/2 Terminated
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT03655613 2022-05-06
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Apollomics (Australia) Pty. Ltd.
Phase 1/2 Terminated
NCT03316222 2022-05-02
Study of GNS561 in Patients With Liver Cancer
Genoscience Pharma
Phase 1/2 Terminated
NCT02102022 2022-04-25
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Polaris Group
Phase 1/2 Terminated
NCT03071094 2021-11-19
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Transgene
Phase 1/2 Terminated
NCT02013778 2020-04-20
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT02828124 2019-01-30
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03035006 2018-11-06
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Taiwan Liposome Company
Phase 1/2 Terminated
NCT01425996 2018-08-21
A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Taiwan Liposome Company
Phase 1/2 Terminated
NCT01020812 2016-07-27
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
Stanford University
Phase 1/2 Terminated
NCT00971126 2016-05-04
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Terminated
NCT01009801 2015-07-07
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Swiss Cancer Institute
Phase 1/2 Terminated
NCT01029418 2015-04-16
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 1/2 Terminated
NCT00081900 2015-04-13
A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
Sanofi
Phase 1/2 Terminated
NCT01128803 2013-11-07
Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response
Nantes University Hospital
Phase 1/2 Terminated
NCT00862082 2013-08-23
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Proacta, Incorporated
Phase 1/2 Terminated
NCT00966251 2012-10-23
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
CureTech Ltd
Phase 1/2 Terminated
NCT00791544 2010-08-04
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Sanofi
Phase 1/2 Terminated
NCT00319683 2008-12-15
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
Adherex Technologies, Inc.
Phase 1/2 Terminated